<unk> , sold under the brand name Jemperli, is a monoclonal antibody used as a medication for the treatment of endometrial cancer. The most common side effects reported in the US include fatigue/asthenia, nausea, diarrhea, anemia, and constipation. Additional common side effects reported in the EU include vomiting, joint pain, itching, rash, fever, and hypothyroidism (low levels of thyroid hormones).<unk>  is a programmed death receptor-1 (PD-1)–blocking monoclonal antibody.<unk>  was approved for medical use in the United States and in the European Union in April 2021.
Dostarlimab
Bezlotoxumab
Tralokinumab
Sacituzumab govitecan
Teprotumumab
Tisotumab vedotin
Ustekinumab
Evolocumab